miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival

(2010) S. Rossi et al.   BLOOD

miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines

(2010) Wei Zhu et al.   INTERNATIONAL JOURNAL OF CANCER

Karyotype-specific microRNA signature in chronic lymphocytic leukemia

(2009) R. Visone et al.   BLOOD

Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia

(2008) M. Vogler et al.   BLOOD

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

(2008) M. Hallek et al.   BLOOD

Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies

(2008) Elisa Barbarotto et al.   CURRENT PHARMACEUTICAL DESIGN

miR-181b negatively regulates activation-induced cytidine deaminase in B cells

(2008) Virginia G. de Yébenes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

MicroRNA expression profiling using microarrays

(2008) Chang-Gong Liu et al.   Nature Protocols

Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL

(2008) Y. Pekarsky et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA